NIH Plans to Disband RAC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Bethesda , Md--NIH director Harold Varmus has announced plants to disband the Recombinant DNA Advisory Committee (RAC). The committee was formed in 1975 as a panel of 24 scientists, ethicists, and others at NIH dedicated to holding those in the field of biogenetics accountable to the public.

Bethesda , Md--NIH director Harold Varmus has announced plantsto disband the Recombinant DNA Advisory Committee (RAC). The committeewas formed in 1975 as a panel of 24 scientists, ethicists, andothers at NIH dedicated to holding those in the field of biogeneticsaccountable to the public.

The RAC created the first safety guidelines for genetically engineeringmicrobes, instituted a formal review system for studies involvinginsertion of new genes into humans, and, in 1990, gave the firstapproval of a human gene therapy experiment. RAC approval wasrequired before the FDA would consider any gene therapy proposal.

Now, Dr. Varmus believes the RAC is no longer necessary, as theFDA can handle all new proposals with the help of ad hoc committeesconvened as needed.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content